Sanofi India Ltd (BSE: 500674) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹7,564 Cr, it ranks #682 by market cap among the 6,197 Indian listed companies on FinBizNet, and #14 of 63 in Pharmaceuticals. At ₹3,300.00 (as of 16 Nov 2026), the share price is 29.0% below its 52-week high of ₹4,650.00 and 19.6% above its 52-week low of ₹2,758.20. The share price is down 30.4% over one year and up 1.6% over three months.
| Current Price | ₹3,300.00 |
|---|---|
| Market Cap | ₹7,564 Cr |
| BSE Code | 500674 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 23.1 |
| Return on Equity | 40.59% |
| Return on Assets | 19.81% |
| 52-Week Range | ₹2,758.20 – ₹4,650.00 |
| 1-Year Price Change | -30.4% |
| 3-Month Price Change | +1.6% |
| Beta (1Y) | 0.32 |
| Dividend Yield | 4.57% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.sanofi.com/en/india/investors |
| Revenue | ₹492 Cr |
|---|---|
| Net Profit | ₹117 Cr |
| Net Margin | 23.7% |
| EPS (Basic) | ₹50.67 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sanofi India Ltd reported revenue of ₹492 Cr in Q2 FY27, up 3.4% from ₹475 Cr in Q2 FY26 and up 12.3% from ₹438 Cr in Q1 FY27. It posted a net profit of ₹117 Cr for the quarter, against a net profit of ₹76 Cr in Q2 FY26 (up 53.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹406 Cr (Q1 FY26) to ₹536 Cr (Q4 FY25). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹492 Cr | ₹117 Cr | 23.7% |
| Q1 FY27 | ₹438 Cr | ₹84 Cr | 19.1% |
| Q4 FY26 | ₹472 Cr | ₹103 Cr | 21.7% |
| Q3 FY26 | ₹420 Cr | ₹62 Cr | 14.7% |
| Q2 FY26 | ₹475 Cr | ₹76 Cr | 16.0% |
| Q1 FY26 | ₹406 Cr | ₹70 Cr | 17.1% |
| Q4 FY25 | ₹536 Cr | ₹120 Cr | 22.3% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 60.40% of Sanofi India Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 46.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
1. Pharmaceutical Business-This segment offers pharmaceutical and related products.
1. Pharmaceutical Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Sanofi India Ltd | ₹7,564 Cr | 23.1 | 40.59% | ₹492 Cr | -30.4% |
Listed by market capitalisation. Ratios are shown for context only.
Sanofi India Ltd is trading at ₹3,300.00, with a market capitalisation of ₹7,564 Cr.
Sanofi India Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sanofi India Ltd has a P/E of 23.1 and a return on equity of 40.59%.
Sanofi India Ltd is listed on the BSE under the scrip code 500674.
Sanofi India Ltd's share price is down 30.4% over one year and up 1.6% over three months. Its 52-week range is ₹2,758.20 to ₹4,650.00.
In Q2 FY27, Sanofi India Ltd reported revenue of ₹492 Cr and net profit of ₹117 Cr, with basic EPS of ₹50.67 (standalone, parsed from the company's exchange filing).
Sanofi India Ltd reported revenue of ₹492 Cr in Q2 FY27, up 3.4% from ₹475 Cr in Q2 FY26 and up 12.3% from ₹438 Cr in Q1 FY27.
Promoters held 60.40% of Sanofi India Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.